Significance of Immunogenic Cell Death-related Genes in Prognosis Prediction and Immune Microenvironment Landscape of Patients with Cutaneous Melanoma

Overview

Journal Front Genet

Date 2022 Oct 10

PMID 36212143

Authors

Weijiang Fu

Guangxin Ma

Affiliations

Soon will be listed here.

Abstract

Cutaneous melanoma (CM) is one of the most life-threatening tumors. Although targeted therapies and immune checkpoint inhibitors have significantly improved patient outcomes over the past decades, they still have their efficacy limitations. Immunogenic cell death (ICD) induces regulated cell death through immunogenic signal secretion and exposure. Accumulated evidence suggests that the ICD process is an effective target for the treatment of a variety of tumor types, including CM. However, the research on ICD in CM is far from complete, and its clinical value has not been widely concerned. By analyzing the Cancer Genome Atlas (TCGA) database, we constructed a new risk model based on 4 ICD-related genes and validated its ability to predict the prognosis of CM patients. In addition, we comprehensively analyzed the tumor microenvironment (TME) of CM patients and showed a significant immunosuppressive TME in the high-risk group compared with the low-risk group. By Immunophenoscore (IPS), we further explored the correlation between the model and immunotherapy response. The data of Genomics of Drug Sensitivity in Cancer (GDSC) database were further extracted to analyze drug sensitivity and evaluate its correlation with the established risk model. In the end, differential expressed genes (DEGs) were analyzed by Gene Set Variation Analysis (GSVA) to preliminarily explore the possible signaling pathways related to the prognosis of ICD and CM. The results of this study provide new perspectives and insights for individualized and accurate treatment strategies for CM patients.

Citing Articles

A model based on immunogenic cell death-related genes predicts prognosis and response to immunotherapy in kidney renal clear cell carcinoma.

Dong P, Zhao L, Zhao L, Zhang J, Lu G, Zhang H Transl Cancer Res. 2024; 13(1):249-267.

PMID: 38410237 PMC: 10894358. DOI: 10.21037/tcr-23-214.

Implications of different cell death patterns for prognosis and immunity in lung adenocarcinoma.

Zhou Y, Gao W, Xu Y, Wang J, Wang X, Shan L NPJ Precis Oncol. 2023; 7(1):121.

PMID: 37968457 PMC: 10651893. DOI: 10.1038/s41698-023-00456-y.

Development of a prognostic model based on anoikis-related genes for predicting clinical prognosis and immunotherapy of hepatocellular carcinoma.

Pang M, Sun X, He T, Liang H, Yang H, Chen J Aging (Albany NY). 2023; 15(19):10253-10271.

PMID: 37787988 PMC: 10599733. DOI: 10.18632/aging.205073.

Development of anoikis-related long non-coding RNA signature associated with prognosis and immune landscape in cutaneous melanoma patients.

Zhong L, Qian W, Gong W, Zhu L, Zhu J Aging (Albany NY). 2023; 15(15):7655-7672.

PMID: 37543428 PMC: 10457054. DOI: 10.18632/aging.204932.

GEO data mining identifies potential immune-related genes in hypertrophic scar and verities in a rabbit model.

Cai H, Liu X, Liu D, Liu B Heliyon. 2023; 9(7):e17266.

PMID: 37455989 PMC: 10338295. DOI: 10.1016/j.heliyon.2023.e17266.

References

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot D, Adam J . Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014; 20(11):1301-9. DOI: 10.1038/nm.3708. View

Berman R, Suzuki T, Tahara H, Robbins P, Narula S, Lotze M . Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol. 1996; 157(1):231-8. View

Le Saux O, Ray-Coquard I, Intidhar Labidi-Galy S . Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol. 2020; 77:127-143. DOI: 10.1016/j.semcancer.2020.08.017. View

Paolini A, Pasi F, Facoetti A, Mazzini G, Corbella F, Liberto R . Cell death forms and HSP70 expression in U87 cells after ionizing radiation and/or chemotherapy. Anticancer Res. 2011; 31(11):3727-31. View

Labi V, Erlacher M . How cell death shapes cancer. Cell Death Dis. 2015; 6:e1675. PMC: 4385913. DOI: 10.1038/cddis.2015.20. View

Bezu L, Gomes-de-Silva L, Dewitte H, Breckpot K, Fucikova J, Spisek R . Combinatorial strategies for the induction of immunogenic cell death. Front Immunol. 2015; 6:187. PMC: 4408862. DOI: 10.3389/fimmu.2015.00187. View

Zhang Q, Li S, Ren J, He X, Shi H, Zhang F . ROS-triggered nanoinducer based on dermatan sulfate enhances immunogenic cell death in melanoma. J Control Release. 2022; 348:22-33. DOI: 10.1016/j.jconrel.2022.04.026. View

Elliott M, Chekeni F, Trampont P, Lazarowski E, Kadl A, Walk S . Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009; 461(7261):282-6. PMC: 2851546. DOI: 10.1038/nature08296. View

Zhao X, Yang K, Zhao R, Ji T, Wang X, Yang X . Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials. 2016; 102:187-97. DOI: 10.1016/j.biomaterials.2016.06.032. View

10.

Chen Q, Daniel V, Maher D, Hersey P . Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer. 1994; 56(5):755-60. DOI: 10.1002/ijc.2910560524. View

11.

Davis L, Shalin S, Tackett A . Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019; 20(11):1366-1379. PMC: 6804807. DOI: 10.1080/15384047.2019.1640032. View

12.

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

13.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I . Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. 2015; 4(4):e1008866. PMC: 4485780. DOI: 10.1080/2162402X.2015.1008866. View

14.

Moriya T, Kitagawa K, Hayakawa Y, Hemmi H, Kaisho T, Ueha S . Immunogenic tumor cell death promotes dendritic cell migration and inhibits tumor growth via enhanced T cell immunity. iScience. 2021; 24(5):102424. PMC: 8102907. DOI: 10.1016/j.isci.2021.102424. View

15.

Reijers I, Menzies A, van Akkooi A, Versluis J, van den Heuvel N, Saw R . Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022; 28(6):1178-1188. DOI: 10.1038/s41591-022-01851-x. View

16.

Dinavahi S, Chen Y, Punnath K, Berg A, Herlyn M, Foroutan M . Targeting WEE1/AKT Restores p53-Dependent Natural Killer-Cell Activation to Induce Immune Checkpoint Blockade Responses in "Cold" Melanoma. Cancer Immunol Res. 2022; 10(6):757-769. PMC: 9177805. DOI: 10.1158/2326-6066.CIR-21-0587. View

17.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

18.

Nikolaou V, Stratigos A . Emerging trends in the epidemiology of melanoma. Br J Dermatol. 2013; 170(1):11-9. DOI: 10.1111/bjd.12492. View

19.

Radogna F, Diederich M . Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy. Biochem Pharmacol. 2018; 153:12-23. DOI: 10.1016/j.bcp.2018.02.006. View

20.

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C . Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009; 15(10):1170-8. DOI: 10.1038/nm.2028. View